Literature DB >> 16831874

The IRAK-1-BCL10-MALT1-TRAF6-TAK1 cascade mediates signaling to NF-kappaB from Toll-like receptor 4.

Wei Dong1, Yingle Liu, Jinhong Peng, Lu Chen, Tingting Zou, Huazhong Xiao, Zhengxue Liu, Wen Li, Yiwen Bu, Yipeng Qi.   

Abstract

Our previous studies have revealed that the signaling protein BCL10 plays a major role in adaptive immunity by mediating NF-kappaB activation in the LPS/TLR4 pathway. In this study, we show that IRAK-1 acts as the essential upstream adaptor that recruits BCL10 to the TLR4 signaling complex and mediates signaling to NF-kappaB through the BCL10-MALT1-TRAF6-TAK1 cascade. Following dissociation from IRAK-1, BCL10 is translocated into the cytosol along with TRAF6 and TAK1, in a process bridged by a direct BCL10-Pellino2 interaction. RNA interference against MALT1 markedly reduced the level of NF-kappaB activation stimulated by lipopolysaccharide (LPS) in macrophages, which suggests that MALT1 plays a major role in the LPS/TLR4 pathway. MALT1 interacted with BCL10 and TRAF6 to facilitate TRAF6 self-ubiquitination in the cytosol, which was strictly dependent on the dissociation of BCL10 from IRAK-1. We show that BCL10 oligomerization is a prerequisite for BCL10 function in LPS signaling to NF-kappaB and that IRAK-1 dimerization is an important event in this process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16831874     DOI: 10.1074/jbc.M513057200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Polyubiquitination of transforming growth factor β (TGFβ)-associated kinase 1 mediates nuclear factor-κB activation in response to different inflammatory stimuli.

Authors:  Anahita Hamidi; Verena von Bulow; Rosita Hamidi; Nicolas Winssinger; Sofia Barluenga; Carl-Henrik Heldin; Marene Landström
Journal:  J Biol Chem       Date:  2011-11-08       Impact factor: 5.157

2.  The adaptor CRADD/RAIDD controls activation of endothelial cells by proinflammatory stimuli.

Authors:  Huan Qiao; Yan Liu; Ruth A Veach; Lukasz Wylezinski; Jacek Hawiger
Journal:  J Biol Chem       Date:  2014-06-23       Impact factor: 5.157

3.  T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1.

Authors:  Jens Staal; Yasmine Driege; Tine Bekaert; Annelies Demeyer; David Muyllaert; Petra Van Damme; Kris Gevaert; Rudi Beyaert
Journal:  EMBO J       Date:  2011-03-29       Impact factor: 11.598

Review 4.  MALT1 protease: a new therapeutic target in B lymphoma and beyond?

Authors:  Linda M McAllister-Lucas; Mathijs Baens; Peter C Lucas
Journal:  Clin Cancer Res       Date:  2011-08-25       Impact factor: 12.531

5.  Endotoxin tolerance impairs IL-1 receptor-associated kinase (IRAK) 4 and TGF-beta-activated kinase 1 activation, K63-linked polyubiquitination and assembly of IRAK1, TNF receptor-associated factor 6, and IkappaB kinase gamma and increases A20 expression.

Authors:  Yanbao Xiong; Fu Qiu; Wenji Piao; Chang Song; Larry M Wahl; Andrei E Medvedev
Journal:  J Biol Chem       Date:  2011-01-10       Impact factor: 5.157

Review 6.  The Paracaspase MALT1.

Authors:  Janna Hachmann; Guy S Salvesen
Journal:  Biochimie       Date:  2015-09-16       Impact factor: 4.079

7.  Carrageenan-induced NFkappaB activation depends on distinct pathways mediated by reactive oxygen species and Hsp27 or by Bcl10.

Authors:  Sumit Bhattacharyya; Pradeep K Dudeja; Joanne K Tobacman
Journal:  Biochim Biophys Acta       Date:  2008-04-11

8.  Experimental Anti-Inflammatory Drug Semapimod Inhibits TLR Signaling by Targeting the TLR Chaperone gp96.

Authors:  Jin Wang; Anatoly V Grishin; Henri R Ford
Journal:  J Immunol       Date:  2016-05-18       Impact factor: 5.422

9.  Modulating temporal control of NF-kappaB activation: implications for therapeutic and assay selection.

Authors:  David J Klinke; Irina V Ustyugova; Kathleen M Brundage; John B Barnett
Journal:  Biophys J       Date:  2008-02-15       Impact factor: 4.033

Review 10.  Toll-like receptor polymorphisms, inflammatory and infectious diseases, allergies, and cancer.

Authors:  Andrei E Medvedev
Journal:  J Interferon Cytokine Res       Date:  2013-05-15       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.